“He signed 17 letters to pharmaceutical companies“Said spokesperson Karoline Leavitt at a press conference, before reading that addressed to the CEO of Eli Lilly, David Ricks. The account of the Head of State, on his Truth Social platform, has in the wake published all the letters, intended for Merck, Novartis, Pfizer, Astrazeneca, Novo Nordisk and Sanofi,If you refuse to act, we will deploy all the means at our disposal to protect American families against abusive practices in terms of the price of drugs“, writes the president in these almost identical letters. He gives them until September 29 to present”firm commitments“In this sense.
On May 12, Donald Trump announced a plan to considerably reduce the prices of medicines in the United States by aligning them with those paid for by other major economies, a promise that he had failed to hold during his first mandate. He mainly intended to obtain these spectacular discounts through negotiations with pharmaceutical groups, opposed in the past to price reductions.
The prices of medicines in the United States are among the highest in the world and surpass those applied to their neighbors and in Europe. On the New York Stock Exchange, the pharmaceutical sector was somewhat heckled by this announcement.
